The Double-Edged Sword of AI Models and Cancer Treatment

Artificial intelligence (AI) has made major advances in biomedical research. It has powered tools such as AlphaFold and systems that help researchers automate and accelerate scientific discovery and review manuscripts. As these models become more widely accessible, The Scientist asked its readers: Will accessible AI models democratize personalized cancer treatment or fuel medical misinformation?

Leena Pattarkine, a biochemist at Harrisburg University of Science and Technology

AI for cancer treatment is definitely a powerful and transformative tool, but there are several challenges due to its functional and reasoning capabilities. For example, the large language model-based tools have created chatbots that can offer instant, on-demand, personalized consultation for patients and healthcare providers; however, authenticity and accuracy pose a challenge. Oversight, alignment with evidence-based algorithm design, and adequate user training are necessary for the democratization of this technology.

Maryam Kazerani Pasikhani, a postdoctoral researcher at Cedars-Sinai Cancer Center

AI models will likely do both, acting as a double-edged sword in personalized cancer treatment. While they can democratize precision medicine by enabling rapid analysis of complex biological data and accelerating the identification of therapeutic targets, their outputs still require rigorous clinical validation before reaching patients; without it, they risk propagating data-driven errors and medical misinformation.

Kagiso Caven Mnisi, a clinical professional at The Global Health Network

If scientists know how to prompt the right way, meaning communicate with the AI models, the ethics of AI will deliver accurate data.

Amit Singh, a postdoctoral researcher at the National Cancer Institute.

Accessible AI models could help democratize personalized cancer treatment by bringing powerful data analysis and clinical insights beyond major research centers. However, without proper validation and oversight, they could also spread medical misinformation—because not everything labeled “AI-powered” is actually intelligent. As we like to joke in science: “Garbage in, garbage out… just faster with AI.” Balancing accessibility with rigor will be key to ensuring real clinical benefit.

Catherine Rono, a postdoctoral researcher at Roswell Park Comprehensive Cancer Center

Accessible AI now places personalized cancer insights within reach of anyone with an internet connection, creating both unprecedented opportunity and real risk. By lowering barriers to complex medical knowledge, these tools can expand access, but their simplicity also increases the potential for misinterpretation.

In many low-resource settings, access to oncology specialists, molecular diagnostics, and up-to-date clinical knowledge remains limited. Accessible AI narrows this gap by translating complex cancer biology into actionable insights, supporting clinicians with limited infrastructure, and helping patients better understand their disease. In this sense, AI can democratize aspects of personalized cancer care that have historically been restricted to well-resourced institutions.

However, this same accessibility introduces risk. AI models often generate confident, simplified outputs that may blur the line between validated clinical evidence and emerging or unproven findings. In settings where health literacy is variable and access to expert guidance is limited, these outputs can be misinterpreted as definitive medical advice, potentially leading to harmful decisions or delayed care.

This makes awareness and education essential. Empowering both patients and healthcare providers to understand the strengths and limitations of AI is critical. AI should be positioned as a supportive tool for information and hypothesis generation, not a substitute for clinical judgment or evidence-based care.

The most effective approach is a balanced one: integrating accessible AI into local healthcare systems, embedding safeguards, ensuring strong data governance, and investing in education. If guided responsibly, AI can reduce disparities in cancer care; without this foundation, it risks widening them through the spread of misinformation. Ultimately, the impact will be shaped not by the technology itself, but by how we choose to implement and understand it.

Responses have been edited for length and clarity.